4CMenB

BIOLOGICAL4 trials

Sponsors

Novartis Vaccines, University of Oxford, GlaxoSmithKline, CHU de Quebec-Universite Laval

Conditions

Infections, MeningococcalMeningitisMeningococcal DiseaseMeningococcal Infections

Phase 2

Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

CompletedNCT00560313

Novartis VaccinesMeningococcal Disease

Start: 2007-07-31End: 2009-11-30Updated: 2016-04-01

Phase 4

Investigating the Immune Response to 4CMenB in Infants

CompletedNCT02080559

University of OxfordMeningitis

Start: 2014-07-21End: 2018-04-27Updated: 2018-10-19

Unknown Phase

Safety of 4CMenB Exposure During Pregnancy

CompletedNCT02640677

GlaxoSmithKlineInfections, Meningococcal

Start: 2016-01-31End: 2019-11-30Updated: 2020-09-03

Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization

CompletedNCT02712177

CHU de Quebec-Universite LavalMeningococcal Infections

Start: 2008-08-31End: 2019-04-30Updated: 2019-08-07

Related Papers

Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials

BMJ Open2019-05-1720 citations